RecruitingNCT05081141

HHV8 and Solid Organ Transplantation

Screening for HHV8 Infection in Solid Organ Transplantation Donors, Candidates and Recipients

Sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Enrollment

250 participants

Start Date

Sep 15, 2021

Study Type

OBSERVATIONAL

Conditions

HHV8 HHV8 Infection HHV8-Related Malignant Neoplasm Kaposi Sarcoma Lung Transplant; Complications Liver Transplant; Complications Kidney Transplant; Complications Castleman Disease

Summary

Solid organ transplant candidates will undergo serological screening for HHV8 at time of listing and transplantation. In the event of a recipient/donor mismatch R-/D+ or in the presence of a seropositive recipient (R+), blood levels of HHV8 DNA will be monitored together with specific IGRA for HHV8.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study is tracking a herpesvirus called HHV-8 (human herpesvirus 8, which causes Kaposi's sarcoma) in organ donors and transplant recipients (kidney, liver, lung) to understand how this virus behaves and spreads through transplantation. **You may be eligible if...** - You are an organ donor being used for kidney, liver, or lung transplantation (including living kidney donors), OR - You are a patient on the transplant waiting list for a kidney, liver, or lung **You may NOT be eligible if...** - There are no exclusion criteria for either group in this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.